VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES - Seite 3

(VRTX-GEN)

TreeFrog Therapeutics

Rachel Mooney
Chief Communications Officer
[e-mail] 

PDF - https://mma.prnewswire.com/media/2394317/TreeFrog_Release.pdf
Logo - https://mma.prnewswire.com/media/2394267/TreeFrog_Therapeutics_and_VERTEX_Logo.jpg

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/vertex-and-treefrog-therapeutics-announce-licensing-agreement-and-collaboration-to-optimize-production-of-vertexs-cell-therapies-for-type-1-diabetes-302123855.html

The Vertex Pharmaceuticals Stock at the time of publication of the news with a raise of +1,43 % to 399,9EUR on Nasdaq stock exchange (23. April 2024, 02:00 Uhr).